This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.
Treatment with L-AmB
Admitted to an ICU or Hematology ward
DNR 2 or 3
Pregnant or lactating women
Previous documentation of intolerance/sensitivity to L-AmB
1. critically ill patients treated with L-AmB 2. hematology patients treated with L-AmB
Case-control
Prospective
Sample collection
Other interventionPlasma, urine, BAL and ascitic fluid sample collection.
Plasma exposure and PK parameters
To document and compare plasma exposure and PK parameters in an ICU vs. non ICU hematology patient cohort in the early and late phase of L-AmB treatment.
Covariates
To document correlating covariates and to stimulate the pharmacokinetics of L-AmB to provide a rationale for optimal dosing strategy in critically ill patients.
Click on the lead sponsor to view all of their trials.
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
KU Leuven
Collaborator
